Loading
CDK2 (Cyclin-dependent kinase 2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Triple-negative breast cancer.
Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CABLES1, CTNNB1, CDK2AP2, ERCC6, NBN, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, SUV39H1, EZH2. Triggers duplication of centrosomes and DNA.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Carboplatin and Eribulin. In OnCo, 1 product record names it (AVZO-021).
In plain words · CDK2 (Cyclin-dependent kinase 2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Triple-negative breast cancer.
CDK2 (Cyclin-dependent kinase 2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Triple-negative breast cancer.
Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis.
No product in this corpus aims at CDK2 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Broadly expressed or essential: HPA lists CDK2 among essential proteins and finds the RNA at low tissue specificity; the 1 medicine aimed at it (AVZO-021) act on the wild-type protein, so normal tissue is exposed and the therapeutic window comes from the tumour's faster division or its dependence on the protein. HPA CDK2: RNA low tissue specificity; no normal tissue stained high; highest cancer staining melanoma (6 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Breast cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas CDK2 tissue; Open Targets ENSG00000123374 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Elledge S.J. et al, EMBO J, 1991, "A new human p34 protein kinase, CDK2, identified by complementation of a cdc28 mutation in Saccharomyces cerevisiae, is a homolog of Xenopus Eg1". Source.
Sources: HGNC HGNC:1771 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P24941 (protein name, function text, keywords and locations (REST API)); CIViC gene CDK2 (1 evidence items, 0 assertions, 1 variants; diseases: Triple-negative Breast Cancer (GraphQL API, CC0))
Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CABLES1, CTNNB1, CDK2AP2, ERCC6, NBN, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, SUV39H1, EZH2. Triggers duplication of centrosomes and DNA. Acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synthesis, and modulates G2 progression; controls the timing of entry into mitosis/meiosis by controlling the subsequent activation of cyclin B/CDK1 by phosphorylation, and coordinates the activation of cyclin B/CDK1 at the centrosome and in the nucleus. Crucial role in orchestrating a fine balance between cellular proliferation, cell death, and DNA repair in embryonic stem cells (ESCs). Activated by the CDK-activating kinase (CAK) complex consisting of CDK7, cyclin-H/CCNH and MAT1, which is a master regulator of CDK activity. Location: Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Nucleus, Cajal body; Cytoplasm; Endosome (UniProt). Locus 12q13.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high; medium in Appendix, Bone marrow, Duodenum, Esophagus, Lymph node, Oral mucosa and more.
RNA cancer enhanced: Skin Cutaneous Melanoma 225 pTPM.
Medium only: breast cancer, carcinoid, colorectal cancer, endometrial cancer.
HPA CDK2 tissue · HPA CDK2 pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CDK2" OR ABSTRACT:"CDK2" OR TITLE:"cyclin dependent kinase 2" OR ABSTRACT:"cyclin dependent kinase 2" OR TITLE:"Cyclin-dependent kinase 2" OR ABSTRACT:"Cyclin-dependent kinase 2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CDK2, not a curated reading list.
Shares Small cell lung cancer (KEGG map), CIViC.
Shares DNA replication & origin licensing, Small cell lung cancer (KEGG map), CIViC, Triple-negative breast cancer (TNBC).
Shares DNA replication & origin licensing, Small cell lung cancer (KEGG map).
Shares Small cell lung cancer (KEGG map), CIViC, Triple-negative breast cancer (TNBC).
Shares DNA replication & origin licensing, Triple-negative breast cancer (TNBC).